By AuntMinnie.com staff writers

October 8, 2019 -- Imaging agent developer ImaginAb said data from the first-in-human imaging study of its CD8 T-cell PET agent for use in detecting solid malignancies were published online October 4 in the Journal of Nuclear Medicine.

The research showed that ImaginAb's CD8 zirconium-89 (Zr-89) IAB22M2C agent was well tolerated with no immediate or delayed side effects, according to the firm. The biodistribution of the agent also suggested that CD8+ T cell-rich tissues were successfully targeted. The observed targeting of tumor lesions indicates the agent may be helpful for assessing the accumulation of CD8+ T cells within tumors, the company said.

The tracer is currently in phase II clinical trials.


Copyright © 2019 AuntMinnie.com
 

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: